Background: Current guidelines recommend that antihyperglycaemic treatment in
Diabetes mellitus is a complex chronic disease characterized by high prevalence, morbidity, and excess mortality. Worldwide, it is estimated that more than 400 million adults are living with diabetes; in particular, the incidence of new cases is increasing in low-and middle-income countries and even in children and adolescents, along with overweight and obesity. Diabetes is a major cause of blindness, kidney failure, heart attack, stroke, and lower limb amputations, leading to a major economic impact on people with diabetes, their families, and the health-care system. 1 A timely type 2 diabetes treatment aiming at blood glucose concentrations close to the normal range reduces the incidence and progression of complications, microvascular, and possibly macrovascular. 2 Management based on lifestyle modifications, medications, and regular screening and treatment of complications and comorbidities is thus strongly advised. 3 If glycaemic targets are not achieved, current guidelines recommend a dual-agent therapy, followed by a triple-agent therapy with two drugs added to metformin. More complex regimens include basal insulin added to other noninsulin agents, premixed insulin, basal-plus (BP), and basal-bolus (BB) insulin therapy. 3, 4 However, despite the polytherapy, many patients are still not reaching their glycated haemoglobin (HbA 1c ) targets and are usually kept on titrated BB. 5, 6 In the last 10 years, glucagon-like peptide-1 receptor agonists (GLP1RAs) have been introduced for type 2 diabetes therapy. On the basis of their pharmacokinetic profile, GLP-1RA can be classified into two classes:
short acting (exenatide and lixisenatide) and long acting (albiglutide, dulaglutide, exenatide long-acting release, liraglutide, and semaglutide).
The former drugs are characterized by their ability to promote a marked reduction in postprandial glucose excursions and rates of gastric emptying, while the latter effectively reduce both fasting and postprandial blood glucose, by stimulating insulin release; both short-and long-acting GLP-1RAs promote reductions in glucagon secretion, blood pressure, and body weight, with low risk of hypoglycaemia. 7 Long-acting GLP1RAs are more effective on HbA 1c compared with short acting, with some of them exhibiting the ability to decrease cardiovascular events and exert a nephroprotective action. [8] [9] [10] The beneficial characteristics of GLP-1RA are preserved when these agents are added to basal or prandial insulin, and fixed combinations of 
| MATERIALS AND METHODS
The systematic review was registered in PROSPERO (CRD4201 7079547) and performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supporting Information). 12 
| Search strategy
A four-step search strategy was planned. First, we identified keywords and MeSH terms in PubMed. Second, the terms "glucagon-like peptide-1 receptor agonist," "short-acting insulin," and "long-acting insulin" (including exenatide, lixisenatide, albiglutide, dulaglutide, liraglutide, semaglutide, aspart, glulisine, lispro, degludec, detemir, and glargine) were searched in PubMed, Scopus, CENTRAL, and ClinicalTrials.gov. Third, randomized controlled trials (RCTs) analysing the following therapy schemes were selected: (1) "short-acting GLP-1RA added to basal insulin" versus "BP/BB"; (2) "long-acting GLP-1RA added to basal insulin" versus "BP/BB"; (3) "long-acting GLP-1RA added to prandial insulin" versus "BP/BB"; and (4) "fixed-ratio combinations of GLP-1RA and basal insulin" versus "BP/BB." Fourth, references of included studies were searched for additional papers.
The last search was performed on 15 July 2018. No language restriction was adopted. Two investigators (M.C. and F.G.) independently searched papers, screened titles and abstracts of the retrieved articles, reviewed the full texts, and selected articles for their inclusion.
| Data extraction
The following information was extracted independently by the same investigators in a piloted form: (1) general information on the study (author, year of publication, study name, study type, follow-up period, number of patients, age, diabetes duration, ethnicity, sex, inclusion criteria of screened population, glucose-lowering medications at prescreening, treatment of randomization, and other antidiabetes therapies allowed during the study) and (2) end points, including HbA 1c , body weight, total daily insulin dose, incidence of hypoglycaemic events, and number of discontinued patients due to lack of efficacy. Confirmed hypoglycaemia was also searched; if missing, any hypoglycaemic event was reported. The main paper and supplementary data were searched; if data were missing, the study protocol and pharmaceutical industry website were searched. Data were crosschecked, and any discrepancy was discussed.
| Study quality assessment
The risk of bias of included studies was assessed independently by two reviewers (M.C. and F.G.) through the Cochrane Collaboration's tool for assessing risk of bias for the following aspects: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selecting reporting. For other bias, funding and authorship were assessed. Each domain was assigned low, unclear, or high risk of bias. 13 
| Data analysis
The primary outcome was the change in HbA 1c from baseline to the last available follow-up. Secondary outcomes included change in body weight from baseline to the last available follow-up, difference in total daily insulin dose at follow-up, incidence of hypoglycaemic events, and discontinuation rate due to lack of efficacy. The first three end points were analysed as continuous variables and summarized as weightedmean difference and the last two as dichotomous variables, and the risk ratios were estimated. If total daily insulin dose was not reported, it was calculated as sum of prandial and basal insulin doses. If standard deviation was missing in a study for a specific outcome, it was calculated from standard error, 95% confidence interval (CI), or interquartile range; if none of these were available, the largest among the other studies was reported. For studies with three arms, the shared one was used for comparison of the other two. In order to assess differences between combination schemes, subgroup analyses on the therapy schemes described in the search strategy section were planned.
Heterogeneity between studies was assessed by using I 2 , with 50% or higher regarded as high. Publication bias was assessed with Egger's test and funnel plot visually; the trim-and-fill method was used for estimating its effect. Sensitivity analyses by removing each study in turn were also performed. All analyses were two sided and were carried out using RevMan5.3 (The Cochrane Collaboration) and Prometa3.0 (Internovi) with a random-effect model; P < 0.05 was regarded as significant.
3 | RESULTS
| Study characteristics
A total of 1885 papers were found, of which 651 on PubMed, 656 on Scopus, 527 on CENTRAL, and 51 on ClinicalTrials.gov; one additional record was identified through other sources. After removal of 550 duplicates, 1335 articles were analysed for title and abstract; 1202 records were excluded (systematic reviews, meta-analyses, not randomized studies, comparison of therapy schemes other than the one reported above, cost-effectiveness studies, studies recruiting patients with type 1 diabetes mellitus, and studies not in humans). The remaining 133 papers were retrieved in full text, and 15 articles, corresponding to 13 trials, were finally included in the systematic review ( Figure 1 ).
| Study quality assessment
The risk of bias of the included studies is shown in the Supporting Information. Random sequence generation and allocation concealment were adequate in eight trials, while for four trials, both procedures
were not reported. 14 
| Qualitative analysis (systematic review)
The characteristics of the included articles are summarized in Table 1 .
The studies were published between 2014 and 2018, had sample sizes ranging from 31 to 894 patients, and had a follow-up from 8 to 52 weeks. All studies were randomized controlled, and eight of them were multinational and sponsored by industry (three by Eli Lilly, two by Novo Nordisk, two by GlaxoSmithKline, and one by Sanofi 25 of 15 to 60 mL/min. In regard to the glucose-lowering therapy at prescreening, 96% of patients were on basal insulin, 27% of patients were on prandial insulin, and 82% of patients were on metformin. Five thousand three hundred eight patients were included, 50% were males, and 77% were FIGURE 1 Flow chart of the systematic review Abbreviations: BB, basal-bolus insulin regimen; BID, twice a day; BMI, body mass index; CPR, C-peptide immune reactivity; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagonlike peptide-1 receptor agonist; HbA 1c , glycated haemoglobin; IDegLira, insulin degludec/liraglutide; MET, metformin; NAFLD, nonalcoholic fatty liver disease; PIO, pioglitazone; QD, every day; QW, every week; RCT, randomized controlled trial.
"x" denotes retrieved data.
Caucasian. The weighted-mean age was 59.3 ± 8.9 years, and the weighted-mean duration of diabetes was 12.9 ± 8.2 years. Two thousand seven hundred forty-four were randomized to GLP-1RA added to insulin, while 2564 to BP/BB insulin regimens.
| Quantitative analysis (meta-analysis)
The Moreover, the subgroup analysis showed a greater ability for the fixed-ratio combination of GLP-1RA and basal insulin to reduce the incidence of hypoglycaemia, when compared with other GLP-1RA-based regimens. No difference in discontinuation due to lack of efficacy was found.
To our knowledge, this is the first systematic review and metaanalysis assessing differences between short-acting and long-acting GLP-1RAs added to insulin in comparison with BP/BB insulin regimens, as well as focusing on end points such as the daily insulin dose and discontinuation due to lack of therapy efficacy. Papers were searched without time restrictions, inclusion criteria were defined prior to the database search, and data were searched on original articles, supplementary data, study protocol, and pharmaceutical industry websites.
Given the strong predictive value for diabetes complications, current guidelines recommend defining a patient's specific HbA 1c goal to be verified at least twice a year. While HbA 1c reflects the average glycaemia over approximately 2 to 3 months, it is not informative for intraday and interday glycaemic variability nor for hypoglycaemia. 3 The main adverse event of some glucose-lowering drugs, specifically insulin, is hypoglycaemia, and this is minimized with GLP-1RA. 29 VII, it could be also due to differences in basal insulin, since insulin degludec is reportedly characterized by reduced rates of hypoglycaemia compared with insulin glargine.
30,31
Type 2 diabetes is often associated with overweight and obesity, exacerbating the morbidity and mortality due to vascular disease.
Current guidelines recommend a weight loss of at least 5% to 10% in these patients, since this is followed by improved glycaemic control and reduced need for medications. 3 Insulin is associated with an increase in body weight of 4.3 ± 2.7 kg/year, while GLP-1RA reportedly promotes weight loss, and one of them, liraglutide, is also approved for the treatment of obesity. 32, 33 This meta-analysis confirms that both For what concerns trial design, studies comparing GLP-1RA with basal or prandial insulin were all included, and differences in therapies other than insulin allowed during the study were found, although their impact could be marginal. Moreover, for example, in AWARD-4 and AWARD-7, patients with a mean HbA 1c at baseline of 8.5% were randomized to dulaglutide or glargine added to lispro; the mean HbA 1c at follow-up was 7.1% and 7.4%, respectively, so a reduced difference in the incidence of hypoglycaemic events between GLP1RAs added to insulin versus BP/BB in AWARD-4 was found as expected, thus leading to the high heterogeneity. 24, 25 Lastly, it should be considered that the studies examined in this review included patients with type 2 diabetes and HbA 1c at baseline between 6%
and 11%, with some of them limiting the enrolment to patients with maximum HbA 1c of 8.5% or 10%, followed up to a maximum of 52 weeks. Whether inclusion of patients with higher HbA 1c levels or followed up for longer periods would have led to different results remains to be assessed.
| CONCLUSION
In patients with type 2 diabetes mellitus, a combination therapy with GLP-1RA and insulin proved to be as effective as BP/BB insulin on 
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article. 
